Item 5.07. Submission of Matters to a Vote of Security Holders.

Pure Bioscience, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting") on February 08, 2023. Of the 111,356,485 shares of the Company's common stock outstanding as of the record date, 65,965,992 shares, or 59.23%, were represented at the Annual Meeting either in person or by proxy.

A description of each matter voted upon at the Annual Meeting is described in detail in the Proxy Statement. The number of votes cast "For" and "Withheld" and "Against" and the number of "Abstentions" and "Broker Non-Votes" with respect to each matter voted upon are set forth below.

(1) Election of Directors. The Company's stockholders elected each of Tom Y. Lee, CPA, Ivan Chen, Tom Myers, Kristin A. Taylor, David M. Rendall, Robert Bartlett, and Bernard Blotner with the approval of 96.67%, 99.19%, 98.33%, 96.60%, 97.38%, 97.35% and 97.34%, of the votes cast, respectively, to hold office until next year's Annual Meeting of Stockholders and until their respective successors are elected and qualified. The following table shows the tabulation of the votes cast For and Withheld with respect to the election of each of the director nominees as well as the Broker Non-Votes submitted for each director nominee:



Director                For           Withheld        Broker Non-Votes
Tom Y. Lee, CPA       52,417,512       1,805,553          11,742,927
Ivan Chen             53,783,287        439,778           11,742,927
Tom Myers             53,317,145        905,920           11,742,927
Kristin A. Taylor     52,377,326       1,845,739          11,742,927
David M. Rendall      52,804,580       1,418,485          11,742,927
Robert Bartlett       52,786,761       1,436,304          11,742,927
Bernard Blotner       52,782,415       1,440,650          11,742,927

(2) Ratification of Auditors. The Company's stockholders ratified the appointment of Weinberg & Company, P.A., with the approval of 99.87% of the votes cast, as the Company's independent registered public accounting firm for the fiscal year ending July 31, 2023. The following table shows the tabulation of the votes cast For and Against this proposal as well as the Abstentions submitted on this proposal:



    For          Against       Abstentions
  65,354,828       78,962         532,202

(3) Executive Compensation. The Company's stockholders, on a non-binding, advisory basis, approved the compensation of the Company's named executive officers, with the approval of 96.84% of the votes cast, as disclosed in the Proxy Statement. The following table shows the tabulation of the votes cast For and Against this proposal as well as the Abstentions and Broker Non-Votes submitted on this proposal:



    For            Against       Abstentions       Broker Non-Votes
  49,699,924       1,617,819        2,905,322          11,742,927

No other items were presented for stockholder approval at the Annual Meeting.

© Edgar Online, source Glimpses